Segall Bryant & Hamill LLC Sells 1,407 Shares of Glaukos Co. (NYSE:GKOS)

Segall Bryant & Hamill LLC lowered its holdings in Glaukos Co. (NYSE:GKOS) by 1.3% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 104,549 shares of the medical instruments supplier’s stock after selling 1,407 shares during the quarter. Segall Bryant & Hamill LLC owned approximately 0.19% of Glaukos worth $15,676,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Mutual of America Capital Management LLC lifted its stake in Glaukos by 1.1% in the fourth quarter. Mutual of America Capital Management LLC now owns 8,353 shares of the medical instruments supplier’s stock worth $1,252,000 after acquiring an additional 89 shares during the period. HighTower Advisors LLC lifted its position in shares of Glaukos by 2.8% in the 4th quarter. HighTower Advisors LLC now owns 3,298 shares of the medical instruments supplier’s stock worth $495,000 after purchasing an additional 91 shares during the period. Louisiana State Employees Retirement System boosted its stake in shares of Glaukos by 0.4% during the 4th quarter. Louisiana State Employees Retirement System now owns 26,700 shares of the medical instruments supplier’s stock valued at $4,003,000 after purchasing an additional 100 shares in the last quarter. Handelsbanken Fonder AB raised its stake in Glaukos by 0.7% in the fourth quarter. Handelsbanken Fonder AB now owns 14,700 shares of the medical instruments supplier’s stock worth $2,204,000 after buying an additional 100 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Glaukos by 2.2% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,956 shares of the medical instruments supplier’s stock worth $1,427,000 after buying an additional 231 shares during the period. 99.04% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on GKOS shares. Stephens raised Glaukos to a “strong-buy” rating in a research report on Monday, December 2nd. UBS Group started coverage on Glaukos in a research report on Friday, December 6th. They set a “buy” rating and a $182.00 price objective for the company. Morgan Stanley downgraded shares of Glaukos from an “equal weight” rating to an “underweight” rating and set a $120.00 target price on the stock. in a research report on Monday, December 2nd. Citigroup raised shares of Glaukos from a “neutral” rating to a “buy” rating and lifted their price target for the company from $132.00 to $162.00 in a research report on Wednesday, December 11th. Finally, BTIG Research upped their price objective on shares of Glaukos from $140.00 to $149.00 and gave the stock a “buy” rating in a report on Tuesday, November 26th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $163.25.

Glaukos Stock Performance

Shares of GKOS opened at $106.72 on Wednesday. The company has a market cap of $6.04 billion, a price-to-earnings ratio of -37.18 and a beta of 0.99. The business’s fifty day simple moving average is $133.61 and its two-hundred day simple moving average is $136.29. Glaukos Co. has a 12 month low of $87.59 and a 12 month high of $163.71. The company has a current ratio of 5.54, a quick ratio of 4.71 and a debt-to-equity ratio of 0.19.

Glaukos (NYSE:GKOS) last released its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.02). Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. The business had revenue of $105.50 million for the quarter, compared to analysts’ expectations of $100.72 million. Research analysts anticipate that Glaukos Co. will post -1.08 earnings per share for the current fiscal year.

Insider Transactions at Glaukos

In related news, insider Tomas Navratil sold 3,416 shares of the stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $147.14, for a total transaction of $502,630.24. Following the transaction, the insider now owns 72,437 shares in the company, valued at $10,658,380.18. This represents a 4.50 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 6.40% of the company’s stock.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.